Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Cortes

Showing results (11-20 of 791) with videos related to

Pageof 80
Sort By:
Blood|December 4, 2025
How can we chop CML with an ASXL1?Jorge Cortes
Hematology. American Society of Hematology. Education Program|December 4, 2020
How to manage CML patients with comorbiditiesJorge Cortes
Blood|November 13, 2012
CML: the good, the better, and the difficult choicesJorge Cortes
Journal of Hematology & Oncology|November 14, 2024
Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD-positive AMLJorge Cortes
Current Hematology Reports|May 4, 2005
Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acidJorge Cortes
Clinical Lymphoma|October 15, 2003
Farnesyltransferase inhibitors in acute myeloid leukemia and myelodysplastic syndromesJorge Cortes
Current Hematology Reports|April 17, 2004
Farnesyl transferase inhibitor R115777 in myelodysplastic syndromeJorge Cortes
Oncology (Williston Park, N.Y.)|October 19, 2013
First-line treatment for patients with CML in chronic phase: second-generation TKIs are the therapy of choiceJorge Cortes
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2011
Considerations in the management of patients with Philadelphia chromosome-positive chronic myeloid leukemia receiving tyrosine kinase inhibitor therapyHagop Kantarjian, Jorge Cortes
Journal of the National Comprehensive Cancer Network : JNCCN|August 9, 2008
BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: using guidelines to make rational treatment choicesHagop Kantarjian, Jorge Cortes
Pageof 80

Showing results (11-20 of 791) with videos related to

Sort By:
Pageof 80
Blood|December 4, 2025
How can we chop CML with an ASXL1?Jorge Cortes
Hematology. American Society of Hematology. Education Program|December 4, 2020
How to manage CML patients with comorbiditiesJorge Cortes
Blood|November 13, 2012
CML: the good, the better, and the difficult choicesJorge Cortes
Journal of Hematology & Oncology|November 14, 2024
Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD-positive AMLJorge Cortes
Current Hematology Reports|May 4, 2005
Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acidJorge Cortes
Clinical Lymphoma|October 15, 2003
Farnesyltransferase inhibitors in acute myeloid leukemia and myelodysplastic syndromesJorge Cortes
Current Hematology Reports|April 17, 2004
Farnesyl transferase inhibitor R115777 in myelodysplastic syndromeJorge Cortes
Oncology (Williston Park, N.Y.)|October 19, 2013
First-line treatment for patients with CML in chronic phase: second-generation TKIs are the therapy of choiceJorge Cortes
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2011
Considerations in the management of patients with Philadelphia chromosome-positive chronic myeloid leukemia receiving tyrosine kinase inhibitor therapyHagop Kantarjian, Jorge Cortes
Journal of the National Comprehensive Cancer Network : JNCCN|August 9, 2008
BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: using guidelines to make rational treatment choicesHagop Kantarjian, Jorge Cortes
Pageof 80